[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 Filing Details: Laura Brege, Director of Edgewise Therapeutics (EWTX), received a stock option grant on June 16, 2025. The transaction involves the following key details:

• Granted 30,000 stock options to purchase common stock
• Exercise price set at $14.68 per share
• Options will vest fully on the earlier of: - June 16, 2026 - Day before 2026 annual stockholder meeting
• Options expire on June 16, 2035

This grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The filing was submitted by John R. Moore as attorney-in-fact for Laura Brege on June 18, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brege Laura

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.68	06/16/2025		A		30,000		06/16/2026(1)	06/16/2035	Common Stock	30,000	$0.00	30,000	D

Explanation of Responses:

1. 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.

Remarks:

	/s/John R. Moore Attorney-in-Fact for Laura A. Brege	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did Laura Brege receive from EWTX on June 16, 2025?

Laura Brege received 30,000 stock options (Right to Buy) from Edgewise Therapeutics (EWTX) on June 16, 2025, with an exercise price of $14.68 per share.

What is the vesting schedule for EWTX stock options granted to Laura Brege in June 2025?

The 30,000 stock options will become 100% vested on the earlier of: (i) June 16, 2026, or (ii) the business day prior to the 2026 annual meeting of stockholders.

When do Laura Brege's EWTX stock options expire?

The stock options granted to Laura Brege have an expiration date of June 16, 2035, giving her a 10-year period to exercise the options from the grant date.

What is Laura Brege's role at EWTX according to the Form 4?

According to the Form 4 filing, Laura Brege serves as a Director of Edgewise Therapeutics (EWTX). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What is the exercise price of EWTX stock options granted to Laura Brege in June 2025?

The stock options were granted with an exercise price of $14.68 per share of EWTX common stock.